Zhi Xiao

Dr. Zhi Xiao


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Protein & Cell
Verified
Journal Article
Open access
PDF file
WMWei Ma
Wei Ma
LZLu Zhang
Lu Zhang
WCWeilong Chen
Weilong Chen
ZCZhaoxia Chang
Zhaoxia Chang
JTJuchuanli Tu
Juchuanli Tu
SLSuling Liu
Suling Liu
Tumor-resident microbiota in breast cancer promote cancer initiation and malignant progression. However, targeting microbiota to improve the effects of breast cancer therapy has not been investigated in detail. Here, we evaluated the microbiota composition of breast tumors and found that enterotoxigenic Bacteroides fragilis (ETBF) was highly enriched in the tumors of patients who did not respond to taxane-based neoadjuvant chemotherapy. ETBF, albeit at low biomass, secreted the toxic protein BFT-1 to promote breast cancer cell stemness and chemoresistance. Mechanistic studies showed that BFT-1 directly bound to NOD1 and stabilized NOD1 protein. NOD1 was highly expressed on ALDH+ breast cancer stem cells (BCSCs) and cooperated with GAK to phosphorylate NUMB and promote its lysosomal degradation, thereby activating the NOTCH1-HEY1 signaling pathway to increase BCSCs. NOD1 inhibition and ETBF clearance increases the chemosensitivity of breast cancer by impairing BCSCs.

20 November 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JPJian Pang
Jian Pang
NDNianhua Ding
Nianhua Ding
XLXuan Liu
Xuan Liu
XHXiongbin He
Xiongbin He
WZWei Zhou
Wei Zhou
ZXZhi Xiao
Zhi Xiao

1 August 2020 in Clinical Breast Cancer
Verified
Journal Article
Closed access
YHYuanping Hu
Yuanping Hu
SWShouman Wang
Shouman Wang
NDNianhua Ding
Nianhua Ding
NLNingsha Li
Ningsha Li
JHJuan Huang
Juan Huang
ZXZhi Xiao
Zhi Xiao

19 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JPJian Pang
Jian Pang
NDNianhua Ding
Nianhua Ding
NYNana Yin
Nana Yin
ZXZhi Xiao
Zhi Xiao
The prognostic value of SII (Systemic Immune-Inflammation Index) in HER-2-positive breast cancer (BC) patients, regardless of whether they receive trastuzumab treatment, and its potential value to distinguish patients who may benefit from trastuzumab therapy, warrant further investigation. Clinical data was collected from 797 HER-2-positive BC patients between July 2013 and March 2018. Baseline data differences were adjusted with propensity score matching. Univariate and multivariate analyses explored the correlation between clinical pathological factors, SII, and DFS. Four groups were established. Based on the baseline SII values of the participants, patients who did not receive trastuzumab treatment were divided into Group 1 (Low-SII) and Group 2 (High-SII), where SII had no predictive value for prognosis between groups. Participants who received trastuzumab treatment were also divided into two groups: the Low-SII group (Group 3) and the High-SII group (Group 4). The 5-year DFS was significantly higher in Group 3 than in Group 4 (91.76% vs. 82.76%, P = 0.017). Furthermore, multivariate analysis demonstrated a significant association between high SII and shorter DFS (HR = 3.430, 95% CI = 1.830–6.420, P < 0.001). In HER-2-positive BC patients treated with trastuzumab, those with lower SII showed a longer DFS, suggesting that SII may help in identifying patients who benefit from trastuzumab therapy.

4 September 2020 in Breast Care
Verified
Journal Article
Open access
PDF file
XDXue Dong
Xue Dong
CLCongfang Liu
Congfang Liu
JYJiaqi Yuan
Jiaqi Yuan
SWShouman Wang
Shouman Wang
NDNianhua Ding
Nianhua Ding
ZXZhi Xiao
Zhi Xiao
Introduction: The neutrophil-to-lymphocyte ratio (NLR) and stromal tumor-infiltrating lymphocytes (sTILs) are associated with immunogenicity and prognosis of patients with triple-negative breast cancer (TNBC). Objective: To investigated the prognostic roles of NLR and sTILs and their rela­tionship of TNBC patients treated with neoadjuvant chemotherapy (NAC). Methods: The clinical data of 170 patients with locally advanced TNBC who received NAC from January 2010 to December 2014 were collected. The difference among variables was calculated by χ2 test. The association between essential clinicopathological characteristics, pathological complete response (pCR), NLR, and sTILs with disease-free survival (DFS) was analyzed. Kaplan-Meier and Cox analysis were performed to address the effects of clinical parameters on prognosis. Results: There was a trend that TNBC patients with lower baseline NLR (NLR1) or higher sTILs scoring would obtain a better pCR rate. NLR1 and sTILs were not associated (p > 0.05). Patients with low NLR1 or high sTILs scoring had a significantly improved DFS compared to those with high NLR1 or low sTILs scoring (p = 0.002 and p = 0.001, respectively). The increased lymphocyte count in peripheral blood after NAC was associated with the improved DFS outcome in both high and low NLR1 groups. Cox analysis revealed that NLR1 and sTILs were independent prognostic predictors of DFS outcome (p < 0.001). Conclusion: Low NLR1 and high sTILs were associated with better DFS outcome in locally advanced TNBC patients treated with NAC. Further studies are needed to explore the connection between systemic and local inflammatory/immune markers.

1 December 2021 in Clinical Breast Cancer
Verified
Journal Article
Closed access
JPJian Pang
Jian Pang
HZHaiyan Zhou
Haiyan Zhou
XDXue Dong
Xue Dong
SWShouman Wang
Shouman Wang
ZXZhi Xiao
Zhi Xiao